AstraZeneca hawks suite of hypertension drugs for $350M by Kyle Blankenship Monday, March 2, 2020 Doubling down on its asset-sale streak, AstraZeneca pawned off five of its hypertension meds to Atnahs Pharma for an upfront payment of $350 million.
Sobi acquires Dova in $915M hematology franchise play by Kyle Blankenship Monday, September 30, 2019 Swedish pharma Sobi is looking for a leg up in hemotology. Can a $915 million buyout of Dova—and its so-far-underperforming drug Doptelet—do the trick?
Sobi rolls more data backing new rare disease drug Gamifant by Carly Helfand Monday, December 3, 2018 Last month, Sobi snagged an FDA approval for rare disease drug Gamifant. And Monday, it unveiled more of the data that secured the agency’s favor.
